Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study

Robert Carreras‐Torres(Centre international de recherche sur le cancer), Mattias Johansson(Centre international de recherche sur le cancer), Philip Haycock(University of Bristol), Kaitlin H. Wade(University of Bristol), Caroline L. Relton(University of Bristol), Richard M. Martin(University Hospitals Bristol NHS Foundation Trust), George Davey Smith(University of Bristol), Demetrius Albanes(National Cancer Institute), Melinda C. Aldrich(Vanderbilt University Medical Center), Angeline S. Andrew(Cotton (United States)), Susanne M. Arnold(University of Kentucky), Heike Bickeböller, Stig E. Bojesen(University of Copenhagen), Hans Brunnström(Lund University), Jonas Manjer(Lund University), Irene Brüske(Helmholtz Zentrum München), Neil E. Caporaso(National Cancer Institute), Chu Chen(Fred Hutch Cancer Center), David C. Christiani(Harvard University), W. Jay Christian(University of Kentucky), Jennifer A. Doherty(Dartmouth College), Eric J. Duell(Institut Català d'Oncologia), John K. Field(University of Liverpool), Michael P.A. Davies(University of Liverpool), Michael W. Marcus(University of Liverpool), Gary E. Goodman(Fred Hutch Cancer Center), Kjell Grankvist(Umeå University), Aage Haugen(National Institute of Occupational Health), Yun‐Chul Hong(Seoul National University), Lambertus A. Kiemeney(Radboud University Nijmegen), Erik H.F.M. van der Heijden(Radboud University Nijmegen), Peter Kraft(Harvard University), Mikael B. Johansson(Centre international de recherche sur le cancer), Stephen Lam(BC Cancer Agency), Maria Teresa Landi(National Cancer Institute), Philip Lazarus(Washington State University Spokane), Loı̈c Le Marchand(University of Hawaiʻi at Mānoa), Geoffrey Liu(Ontario Institute for Cancer Research), Olle Melander(Lund University), Sungshim L. Park(University of Southern California), Gad Rennert(Technion – Israel Institute of Technology), Angela Risch(University of Salzburg), Eric B. Haura(Moffitt Cancer Center), Ghislaine Scélo(Centre international de recherche sur le cancer), Давид Заридзе(Russian Cancer Research Center NN Blokhin), Anush Mukeriya(Russian Cancer Research Center NN Blokhin), Milan Savić(Centar za Promociju Nauke), Jolanta Lissowska(The Maria Sklodowska-Curie National Research Institute of Oncology), Beata Świątkowska(Nofer Institute of Occupational Medicine), Vladimí­r Janout(University of Ostrava), Ivana Holcátová(Charles University), Dana Mateș, Matthew B. Schabath(Moffitt Cancer Center), Hongbing Shen(Nanjing Medical University), Adonina Tardón(Universidad de Oviedo), M. Dawn Teare(University of Sheffield), Penella J. Woll(University of Sheffield), Ming‐Sound Tsao(Princess Margaret Cancer Centre), Xifeng Wu(The University of Texas MD Anderson Cancer Center), Jian‐Min Yuan(University of Pittsburgh), Rayjean J. Hung(Mount Sinai Hospital), Christopher I. Amos(Dartmouth College), James McKay(Centre international de recherche sur le cancer), Paul Brennan(Centre international de recherche sur le cancer)
PLoS ONE
June 8, 2017
Cited by 665Open Access
Full Text

Abstract

BACKGROUND: Assessing the relationship between lung cancer and metabolic conditions is challenging because of the confounding effect of tobacco. Mendelian randomization (MR), or the use of genetic instrumental variables to assess causality, may help to identify the metabolic drivers of lung cancer. METHODS AND FINDINGS: We identified genetic instruments for potential metabolic risk factors and evaluated these in relation to risk using 29,266 lung cancer cases (including 11,273 adenocarcinomas, 7,426 squamous cell and 2,664 small cell cases) and 56,450 controls. The MR risk analysis suggested a causal effect of body mass index (BMI) on lung cancer risk for two of the three major histological subtypes, with evidence of a risk increase for squamous cell carcinoma (odds ratio (OR) [95% confidence interval (CI)] = 1.20 [1.01-1.43] and for small cell lung cancer (OR [95%CI] = 1.52 [1.15-2.00]) for each standard deviation (SD) increase in BMI [4.6 kg/m2]), but not for adenocarcinoma (OR [95%CI] = 0.93 [0.79-1.08]) (Pheterogeneity = 4.3x10-3). Additional analysis using a genetic instrument for BMI showed that each SD increase in BMI increased cigarette consumption by 1.27 cigarettes per day (P = 2.1x10-3), providing novel evidence that a genetic susceptibility to obesity influences smoking patterns. There was also evidence that low-density lipoprotein cholesterol was inversely associated with lung cancer overall risk (OR [95%CI] = 0.90 [0.84-0.97] per SD of 38 mg/dl), while fasting insulin was positively associated (OR [95%CI] = 1.63 [1.25-2.13] per SD of 44.4 pmol/l). Sensitivity analyses including a weighted-median approach and MR-Egger test did not detect other pleiotropic effects biasing the main results. CONCLUSIONS: Our results are consistent with a causal role of fasting insulin and low-density lipoprotein cholesterol in lung cancer etiology, as well as for BMI in squamous cell and small cell carcinoma. The latter relation may be mediated by a previously unrecognized effect of obesity on smoking behavior.


Related Papers